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ABSTRACT: The direct activation of cannabinoid receptors
(CBRs) results in several beneficial effects; therefore several
CBRs ligands have been synthesized and tested in vitro and in
vivo. However, none of them reached an advanced phase of
clinical development due mainly to side effects on the CNS.
Medicinal chemistry approaches are now engaged to develop
allosteric modulators that might offer a novel therapeutic
approach to achieve potential therapeutic benefits avoiding
inherent side effects of orthosteric ligands. Here we identify the first ever synthesized positive allosteric modulator (PAM) that
targets CB2Rs. The evidence for this was obtained using [
3H]CP55940 and [35S]GTPγS binding assays. This finding will be
useful for the characterization of allosteric binding site(s) on CB2Rs which will be essential for the further development of CB2R
allosteric modulators. Moreover, the new CB2R PAM displayed antinociceptive activity in vivo in an experimental mouse model
of neuropathic pain, raising the possibility that it might be a good candidate for clinical development.
■ INTRODUCTION
The endocannabinoid system (ECS) is a ubiquitous neuro-
modulatory system with wide-ranging actions.1 Cannabinoid
receptors (CB1Rs, CB2Rs) are members of G-protein-coupled
receptors family. Several findings indicate that CB2R ligands,
which do not share the ability of CB1R agonists to produce
psychotropic effects or of selective CB1R antagonists to
produce other serious adverse effects,2−4 appear to be
promising drugs for treating several diseases.5−7 Medicinal
chemistry approaches are now being adopted to develop more
efficacious agonists and in particular to investigate the
possibility of developing allosteric modulators (Figure 1) that
might offer a novel therapeutic approach with minimal side
effects. It has been reported that CBRs have spatially distinct
allosteric sites that can be targeted by exogenous/endogenous
substances modulating the receptors’ functional state.8−15
Allosteric modulators offer numerous advantages with respect
to orthosteric ligands, such as a greater subtype selectivity for
the higher sequence divergence at allosteric sites, than the
orthosteric domains; furthermore, allosteric modulators
possess tissue selectivity because they exert effects only
where endocannabinoids are present and eventually they
might provide synergizing effects with other coadministered
ECS modulators.16−19 Moreover, they could have the
advantage of activating or inhibiting the biased signaling
properties of these GPCRs. For these reasons, allosteric
modulators might represent a valid alternative method to
Special Issue: Allosteric Modulators
Received: March 8, 2018
Published: July 10, 2018
Figure 1. General classification of allosteric modulators: PAMs,
NAMs, and SAMs.
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modulate the ECS and they could be useful for the
development of future drugs. They are classified as positive
allosteric modulators (PAMs) or negative allosteric modulators
(NAMs) which activate or inhibit the receptor response,
respectively, neutral or silent allosteric modulators, which do
bind to the allosteric site without affecting the response of the
endogenous agonist, and bitopic ligands that bind to both the
orthosteric and allosteric sites.
To date, few allosteric modulators for CB1Rs have been
developed. Among them, indole derivatives,9,20 urea deriva-
tives,21 and certain other molecules have a PAM profile (Figure
2).22 Up to now, the only CB2R allosteric modulator reported
in the literature is the endogenous pepcan-12 (Figure 2) which
was reported also to be a CB1R NAM.
23
In this work, we present evidence that the novel synthetic
compound C2 (Figure 3) is a positive allosteric modulator
(PAM) of the CB2Rs. This evidence was obtained by carrying
out [3H]CP55940 and [35S]GTPγS binding assays. C2 is a
member of a group of compounds that were obtained by
modifying the structure of 2-oxopyridine-3-carboxamides
derivatives of general structures A and B (Figure 3) that had
been previously shown to be orthosteric CBR ligands.24 With
the aim of deeply exploring the structure−activity relationships
of derivatives A and B, we synthesized derivatives C1−C5,
D1−D6, and E1 in which the amide group in position C-3 of
the 2-oxopyridine-3-carboxamides A and B was substituted
with the corresponding retro-amide (Figure 3). The
substituents of derivatives C and D have been selected on
the basis of the best results achieved with the series A and B.
Moreover, compound E1, characterized by an OH group in
position 4, has been synthesized to understand the role of the
methyl group and, at the same time, to define the effect on the
affinity of binding to CBRs of a polar group in the same
position (Figure 3). Finally, derivative C2 displayed anti-
nociceptive activity in vivo in an experimental mouse model of
neuropathic pain.
■ RESULTS AND DISCUSSION
Chemistry. The synthesis of 2-oxopyridines C, D, and E1
was obtained as reported in Schemes 1−3.
The cycloheptanecarboxamide derivatives C1−C5 were
synthesized (Scheme 1) starting from the 2-hydroxy-4-
methyl-3-nitropyridine which underwent a catalytic hydro-
genation to afford derivative 1. The reaction between the
amine 1 and the cycloheptanecarbonyl chloride in toluene,
DMF, and triethylamine, carried out initially at 0 °C and then
at 30 °C for 48 h, afforded the amide 2. The acyl chloride was
prepared from reaction between cycloheptanecarboxylic acid
with SOCl2 at 76 °C for 3 h. The derivative 2 was reacted with
CsF and then with p-fluorobenzyl chloride, yielding the desired
N-alkylated compound C1. The derivatives C2−C5 were
synthesized starting from the amide 2 which was treated with a
Figure 2. Representative CBRs allosteric modulators.
Figure 3. Design of retro-amides C1−C5, D1−D6, and E1.
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solution of bromine in CHCl3, affording the corresponding 5-
bromo derivative 3. The treatment of 3 with p-fluorobenzyl
chloride via a similar method to that used for the preparation
of C1, afforded the desired N-alkylated compound C2
(Scheme 1). The 5-aryl derivatives C3 and C4 were yielded
starting from the 5-bromo derivative C2 via a Suzuki−Miyaura
cross-coupling reaction with the suitable boronic acids in dry
toluene and Pd(PPh3)4 as catalyst (Scheme 1). The 5-chloro
derivative C5 was obtained from amide 2 which was treated
with N-chlorosuccinimide to give compound 4. The N-
alkylation of 4, carried out following the same method used
to yield C1−C4, afforded the desired compound C5 (Scheme
1).
As reported in Scheme 2, compounds D1−D6 were
obtained starting from 2-hydroxy-6-methyl-3-nitropyridine
which underwent a catalytic hydrogenation, using Pd/C as
catalyst, to afford compound 5. Subsequently, the condensa-
tion of 5 with cycloheptanecarboxylic acid using TBTU as
condensing reagent in the presence of triethlylamine yielded
the carboxamide 6 which, for N-alkylation with NaH, LiBr, and
p-fluorobenzyl chloride, gave D1. The reaction of 6 with a
solution of bromine in CHCl3 produced the corresponding 5-
bromo derivative 7, which was N-alkylated by the same
procedure previously described to yield the desired compound
D2. The derivatives D3 and D4 were obtained from D2 by
Suzuki cross-coupling reaction with the suitable arylboronic
acid (Scheme 2). The reaction of compound 6 with N-
chlorosuccinimide in acetonitrile at reflux gave the 5-chloro
derivative 8 which was N-alkylated using the procedure already
described, to afford compound D5 (Scheme 2). The
carboxamide 6 was also treated with 1-chloromethyl-4-fluoro-
1,4-diazoniabicyclo[2.2.2]octanebis(tetrafluoroborate) in ace-
tonitrile at reflux for 12 h, yielding the 5-fluorinated derivative
9 which was N-alkylated to afford the desired compound D6
(Scheme 2).
Finally, compound E1 was synthesized as reported in
Scheme 3, starting from 4-hydroxy-3-nitro-2-oxo-1,2-dihydro-
pyridine which underwent a catalytic hydrogenation to yield
derivative 10. Reaction of 10 with cycloheptanecarbonyl
chloride prepared as reported above gave compound 11
which, by treatment with a solution of bromine in CHCl3,
yielded compound 12. The N-alkylation of 12 carried out with
CsF and p-fluorobenzyl chloride afforded the derivative E1.
[3H]CP55940 Binding Assays. Compounds C1−C5, D1−
D6, and E1 were evaluated for CBRs binding by incubating
these compounds with membrane preparations obtained from
Chinese hamster ovary (CHO) cells overexpressing hCB1Rs or
hCB2Rs in the presence of 0.7 nM [
3H]CP55940, a high-
affinity orthosteric CB1R and CB2R radioligand. Also, the N1-
unsubstituted analogue of C2, derivative 3, was assayed with
the aim of exploring the influence of the substituent in position
1.
Regarding the CB1Rs, initially, all compounds were screened
at 100 nM. The results (Figure S1 in Supporting Information)
showed that only compounds C1, D1, D5 and derivative 3
displaced [3H]CP55940. Rather unexpectedly, all the other
compounds enhanced the binding of the radioligand to CB1Rs.
In particular, compounds C2, C3, and D3 were found to be
effective as enhancers at 100 nM (Figure S1 in Supporting
Information) and their concentration-dependent (1 nM to 1
μM) CB1R binding curves (C3 and D3 Figure S2 in
Supporting Information) indicated compound C2 (Figure 4)
to be the best enhancer, inducing approximately a 40%
increase in the binding of [3H]CP55940 up to a concentration
of 1 μM. However, no increase in such binding was induced by
C2 at 10 μM. These data suggest that C2 may be a CB1R PAM
(Figure 4).
In the case of the CB2Rs, concentration-dependent binding
curves (Figure S3 in Supporting Information) indicate that
D1−D6, C1, C3−C5, and 3 were either weak orthosteric
ligands or completely inactive. Derivative E1 was found to
enhance weakly the binding of [3H]CP55940 (Figure S3 in
Supporting Information), whereas compound C2 strongly
increased the binding of [3H]CP55940 at very low
concentrations (Figure 4) raising the possibility that it may
be a CB2R PAM.
[35S]GTPγS Assays. To evaluate the functional activity of
C2 on CBRs, [35S]GTPγS assays were carried out in the
presence of [35S]GTPγS (0.1 nM), GDP (30 μM), GTPγS (30
μM), with CHO cell membranes (1 mg/mL) overexpressing
hCB1Rs or hCB2Rs and in the presence of CP55940, a full
agonist of both CBRs. The choice of a C2 concentration of
100 nM for these experiments was influenced by CB1R and
CB2R binding data. The effects of C2 on the modulation of
CBR-mediated signaling were studied by measuring
[35S]GTPγS receptor binding (Figure 5).
The CP55940-induced stimulation of [35S]GTPγS CB1R
binding was not significantly altered by 100 nM C2 (Figure 5).
This result suggests that although this concentration of
compound C2 increases the binding of the orthosteric ligand
[3H]CP55940 to CB1Rs, this enhancement does not
significantly affect the ability of CP55940 to activate CB1Rs.
Scheme 1. Synthesis of Compounds C1−C5a
aReagents and conditions: (i) H2, Pd/C, MeOH, rt, 12 h; (ii) (1)
cycloheptanecarboxylic acid, SOCl2, 76 °C, 3 h; (2) acyl chloride,
toluene, DMF, NEt3, 0−32 °C, 48 h; (iii) (1) DMF, CsF, rt, 1 h; (2)
p-fluorobenzyl chloride, 50 °C, 12 h; (iv) Br2, CHCl3, 30 °C, 12 h;
(v) triphenylphosphine, Pd(OAc)2, K2CO3, suitable arylboronic acid,
110 °C, 12 h; (vi) N-chlorosuccinimide, ACN, reflux, 12 h.
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However, the current data are not sufficient to indicate C2 as
SAM for CB1R.
Conversely C2 appeared to target CB2Rs in a very promising
and interesting manner (Figure 5). Thus, the ability of
CP55940 to stimulate [35S]GTPγS binding to CB2Rs was
significantly enhanced by 100 nM C2. Furthermore, as shown
in Figure S4 (Supporting Information), in the absence of the
orthosteric ligand, compound C2 did not produce any
stimulation or inhibition of [35S]GTPγS binding to CB2Rs.
Collectively, these data suggest that C2 acts as a PAM of
CB2Rs.
Further studies should be carried out with the aim to
investigate the allosteric effects of C2 more fully (e.g., more
concentrations and additional functional in vitro assays) and to
highlight different behaviors at other CB1R- and CB2R-
mediated signaling pathways (e.g., cAMP production, β-
arrestin, ion channels).
Consequently, the study of this compound was extended by
performing [35S]GTPγS receptor binding assays using one or
the other of the two major endocannaboinoids, anandamide
(AEA) and 2-arachidonoylglycerol (2-AG), as CB2R agonists,
rather than CP55940. As shown in Figure 6, 100 nM C2
significantly enhanced the stimulation of [35S]GTPγS binding
to CB2R induced by 2-AG but not the enhancement induced
by AEA. Thus, it is likely that C2 would be able to facilitate the
activation of CB2Rs by low concentrations of endogenously
released 2-AG, although not by endogenously released AEA.
Dissociation Kinetic Assays. In order to better character-
ize the postulated allosteric action of derivative C2, some
dissociation kinetic assays in the absence or in the presence of
C2 (Figure 7) were performed. These assays were carried out
with the CB1/CB2R ligand [
3H]CP55940 (1 μM), C2 (100
nM), and CHO cell membranes (1 mg/mL) overexpressing
hCB2Rs. Dissociation was monitored from +0.5 to +120 min at
Scheme 2. Synthetic Pathway for Compounds D1−D6a
aReagents and conditions: (i) H2, Pd/C, MeOH, rt, 12 h; (ii) cycloheptanecarboxylic acid, TBTU, NEt3, DMF, 0 °C rt, overnight; (iii) NaH 60%,
LiBr, p-fluorobenzyl chloride, DMF, DME, 65 °C, 12 h; (iv) Br2, CHCl3, rt, 12 h; (v) triphenylphosphine, Pd(OAc)2, K2CO3, suitable arylboronic
acid, 110 °C, overnight; (vi) N-chlorosuccinimide, ACN, reflux, 12 h; (vii) 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octanebis-
(tetrafluoroborate), ACN, reflux, 12 h.
Scheme 3. Synthetic Pathway for Compound E1a
aReagents and conditions: (i) H2, Pd/C, MeOH, rt, 12 h; (ii) (1) cycloheptanecarboxylic acid, SOCl2, 76 °C, 3 h; (2) toluene, DMF, NEt3, 0−32
°C, 48 h; (iii) Br2, CHCl3, 30 °C, 12 h; (iv) (1) DMF, CsF, rt, 1 h; (2) p-fluorobenzyl chloride, 50 °C, 12 h.
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25 °C. As shown in Figure 7, [3H]CP55940 dissociation was
completely prevented by 100 nM C2 for at least 2 h. The
absence of [3H]CP55940 dissociation from CB2Rs was in line
with the increased binding of [3H]CP55940 induced by C2 in
binding experiments. These findings support our hypothesis
that C2 targets an allosteric binding site of the CB2Rs. Each
point on the graph represents a mean of four replicates.
Inhibitory Activity on MAGL. Finally, in line with the
hypothesis that C2 enhanced 2-AG-induced stimulation of
[35S]GTPγS binding to the CB2Rs by acting as a CB2R PAM,
evidence was obtained that C2 did not induce this enhance-
ment by inhibiting monoacylglycerol lipase (MAGL), the main
2-AG degrading enzyme. This evidence was obtained from
experiments in which the enzymatic activity of human isoforms
of MAGL was measured by using a colorimetric assay that
exploits 4-nitrophenylacetate (4-NPA) as a nonspecific
chromogenic substrate for MAGL and by measuring the
absorbance values at 405 nm due to 4-nitrophenol (PNP)
released from 4-NPA, upon enzymatic hydrolysis.25 The
obtained results showed that C2 produced no significant
inhibition of MAGL at <10 μM.
Antinociceptive Effects of C2 in Animal Models of
Neuropathic Pain. Neuropathic pain may be induced by
traumatic injury, metabolic challenges, and chemotherapeutic
agents. Pharmacotherapies used to treat neuropathic pain
produce inadequate pain relief and/or unwanted side effects.
Thus, the identification of novel therapeutic approaches with
limited side effect profiles remains an urgent medical need.
Cannabinoids suppress behavioral responses to noxious
stimulation and suppress nociceptive transmission through
activation of CB1Rs and CB2Rs. Moreover, the CB2Rs are
upregulated in the CNS and dorsal root ganglia by pathological
pain states, and they were identified as a therapeutic target for
treating pathological pain states.26 These observations
prompted us to examine the ability of C2 to alleviate signs
of neuropathic pain in a mouse model of nociceptive behavior
caused by the chemotherapeutic agent, oxaliplatin (OXP).
A daily treatment with the neurotoxic compound oxaliplatin
(2.4 mg kg−1 intraperitoneally, ip) progressively decreased the
pain threshold of mice evaluated as hypersensitivity to a cold
non-noxious stimulus (allodynia-like measurements; cold plate
test).27 The licking latency decreased to 9.7 ± 0.9 s in
comparison to control mice (18.2 ± 0.6 s) treated with vehicle
(Figure 8). The effect of single oral (po) administration of four
different doses of derivative C2 (1, 5, 10, 20 mg kg−1) on
oxaliplatin-treated mice is shown in Figure 8. C2 significantly
increased licking latency in the animals starting from 5 mg
Figure 4. Effects of compounds C2 (at 1 nM to 10 μM) on
[3H]CP55940 binding to CB1R (left) and CB2R (right). Asterisks
indicate mean values significantly different from zero (*P < 0.05; **P
< 0.01; ****P < 0.0001) (one sample t test). Data are expressed as
the mean ± SEM of six independent experiments, each performed in
duplicate.
Figure 5. CB1R [
35S]GTPγS binding assays (left) and CB2R
[35S]GTPγS binding assays (right) performed with CP55940 and
compound C2. Asterisks indicate mean values significantly different
from zero (*P < 0.05; **P < 0.01; ***P < 0.001) (Student’s unpaired
t test). Data are expressed as the mean ± SEM of six and 12
independent experiments for CB1R and CB2R, respectively, each
performed in duplicate.
Figure 6. CB2R [
35S]GTPγS binding assays performed in the
presence of C2 with 2-arachidonoylglycerol (2-AG) (left) or
anandamide (AEA) (right). Asterisks indicate mean values signifi-
cantly different from zero (*P < 0.05; **P < 0.01) (Student’s
unpaired t test). Data are expressed as the mean ± SEM of six
independent experiments, each performed in duplicate.
Figure 7. Dissociation of [3H]CP55940 from CB2Rs in the presence
or absence of C2. Data are expressed as the mean ± SEM of four
independent experiments, each performed in duplicate.
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kg−1. The doses of 5 and 10 mg kg−1 of C2 were equally
effective between 30 and 60 min after administration (Figure
8). The effect of the higher 20 mg kg−1 dose was detectable
within 15 min and lasted 60 min, reducing animal pain
threshold back to the value of controls between +30 and +45
min.
Additional experiments were performed to establish if an
increase in endocannabinoid levels induced by a mono-
acylglycerol lipase (MAGL) inhibitor would potentiate the
effect of C2. The used MAGL inhibitor F (compound 4a in ref
28) was previously reported in literature and it was shown to
be efficacious in the same model of neuropathic pain.28 It was
administered po at a minimum active dose of 1 mg kg−1 15
min before compound C2 (used at the completely inactive
dose 1 mg kg−1 and the partially effective dose 10 mg kg−1).
The effect observed after the coadministration of C2 with the
MAGL inhibitor was significantly increased in comparison to
that produced by each compound administered alone (Figure
9). The lowest dose of C2 (1 mg kg−1) became able to fully
revert oxaliplatin-induced hypersensitivity when administered
after the MAGL inhibitor F (1 mg kg−1). The analysis of
synergism performed by the Chou−Talalay method29 revealed
a combination index (CI; CompuSyn software) of 0.20123
considered as “synergism”. MAGL inhibitor, administered
alone at dose 1 mg kg−1, had a partial pain relieving efficacy
(Figure 9).
Finally, the possible predominance of a CBR subtype in the
antineuropathic effect of C2 was studied. Selective CB1R
(SR141716A) and CB2R (SR144528) antagonists were
administered ip 15 min before C2 (20 mg kg−1 po; Figure
10). The efficacy of C2 was strongly decreased by pretreating
with SR144528 (10 mg kg−1 ip), whereas SR141716A only
reduced the duration of C2 effect without affecting its
antihyperalgesic efficacy. A main involvement of CB2Rs is
indicated as pharmacodynamic mechanism of C2 efficacy
against chemotherapy-induced neuropathic pain.
■ CONCLUSION
We have presented evidence that compound C2 is the first ever
synthesized CB2R PAM. This compound was obtained from
the CBR orthosteric ligands, 2-oxopyridine-3-carboxamide,
simply by changing its amide side chain into a retro-amide side
chain.
Figure 8. Neuropathic pain modulation by C2. Hypersensitivity was
induced by repeated treatment with oxaliplatin, the response to a
thermal stimulus was evaluated by the cold plate test measuring the
latency (s) to pain-related behaviors (lifting or licking of the paw).
Tests were performed on day 15. C2 or vehicle were administered po,
measurements were performed 15, 30, 45, 60, and 75 min after
treatment. Each point on the graph represents a mean of 16 individual
values obtained from 16 mice analyzed in 2 different experimental
sets. ∧∧P < 0.01 vs vehicle + vehicle treated mice. *P < 0.05 and **P <
0.01 vs oxaliplatin + vehicle treated mice. ANOVA followed by
Bonferroni test was performed.
Figure 9. Neuropathic pain. Effect of C2 administered 15 min after
the MAGL inhibitor F. Measurements were performed 15, 30, 45, 60,
and 75 min after the administration (cold plate test). Control mice
were treated with vehicle. Each point on the graph represents a mean
of 16 individual values obtained from 16 mice analyzed in 2 different
experimental sets. ∧∧P < 0.01 vs vehicle + vehicle treated mice. *P <
0.05 and **P < 0.01 vs oxaliplatin + vehicle treated mice. °°P < 0.01
vs oxaliplatin + C2 treated mice. ANOVA followed by Bonferroni test
was performed.
Figure 10. Neuropathic pain. Effects of CB1R and CB2R antagonism
on C2 pain relieving efficacy. Measurements were performed 15, 30,
45, 60, and 75 min after the administration of C2. Control mice were
treated with vehicle. Each point on the graph represents a mean of 16
individual values obtained from 16 mice analyzed in 2 different
experimental sets. ∧∧P < 0.01 vs vehicle + vehicle treated mice. *P <
0.05 and **P < 0.01 vs oxaliplatin + vehicle treated mice. ANOVA
followed by Bonferroni test was performed.
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Derivative C2 behaved as a potent CB2R PAM as indicated
by its ability, at 1 nM to 1 μM, to produce marked increases in
the binding of [3H]CP55940 to CB2Rs. At 100 nM, C2 also
significantly enhanced the ability of CP55940 and 2-AG, but
not of AEA, to stimulate [35S]GTPγS binding to CB2Rs. As
expected for an allosteric modulator, C2 did not affect signs of
CB2R receptor signaling in the [
35S]GTPγS assay, in the
absence of a CB2R agonist. Interestingly, C2 significantly
improved the ability of 2-AG, but not of AEA, to stimulate
[35S]GTPγS binding to CB2Rs. Thus, derivative C2 would be
able to activate CB2Rs by low concentrations of endogenously
released 2-AG, and also it could potentiate the pharmaco-
logical activity of MAGL inhibitors.
Although we studied only a small compound library, the
obtained results suggest that the C and D series of compounds
display interesting SARs. Undoubtedly, it was the introduction
of a retro-amide side chain into compounds A and B that
converted them into CB2R allosteric modulators (C and D).
Also the bromo substituent in position 5 seems to be
important because its replacement with an H or with other
groups abolished all signs of allosteric activity. Furthermore,
the substitution of the methyl group in position 4 with an OH
group (compound E1) reduced signs of allosteric activity. The
display of such activity also seems to require the presence of a
substituent at position 1 of the pyridine ring, as suggested by
the finding that compound 3 lacks any detectable allosteric
activity.
The new CB2R PAM, C2, was tested in cold allodynia assays
to investigate its effect on neuropathic pain. Results showed
that derivative C2, after oral administration, dose-dependently
reversed the lowering of the threshold to cold stimuli (cold
plate test) induced by oxaliplatin. As demonstrated by
pharmacological antagonism, this effect is predominantly
mediated by the CB2Rs.
Finally, C2 potentiated the antiallodynic effect of the MAGL
inhibitor F, which previously showed it to be efficacious in the
same model of neuropathic pain.28
Our findings support our hypothesis that compound C2 acts
as a CB2R PAM both in vitro and in vivo. Moreover, C2 could
beneficially influence the CNS damages induced by neuro-
pathies. Several cell types (including microglia, astrocytes, and
oligodendrocytes) are involved in the maladaptive plasticity of
the nervous tissue that is thought to be the basis of chronic
pain states.30 The widespread expression (for anatomic areas
and cell types)31 of the CB2Rs makes its regulation a powerful
therapeutic approach. The antinociceptive effects of C2 need
to be further explored as this compound might be a good
candidate for clinical development. Recently, based on a
homology model, an allosteric binding pocket was postulated
to exist adjacent to the CB2R orthosteric binding site.
8,14 The
CB2R PAM C2 could be useful for the characterization of such
putative binding site(s), a crucial step for the future
development of CB2R allosteric modulators. In addition, a
better understanding of the physiological consequences of
CB2R allosteric modulation might lead to novel pharmaco-
therapies that rely on this pharmacological action.
■ EXPERIMENTAL SECTION
Chemistry. Commercially available reagents were purchased from
Sigma-Aldrich or Alfa Aesar and used without purification. 1H NMR
and 13C NMR spectra were recorded on a Bruker AVANCE III 400
spectrometer (operating at 400 MHz). Chemical shifts (δ) are
reported in parts per million related to the residual solvent signal,
while coupling constants (J) are expressed in hertz (Hz) Catalitic
hydrogenation was performed with CLAIND H2 generator, type
HG2200 (flow meter, 200 mL/min; outlet pressure, 1−6 bar;
operating temperature, 5−40 °C). A Bechman HPLC instrument
equipped with a System Gold solvent delivery module (pumps) 125,
System Gold UV/vis detector 166, detector set to 280 nm was
employed. Analyses were performed on a reverse phase C18 column
(Phenomenex 250 mm × 4.6 mm, 5 mm particle size, Gemini). The
mobile phase was constituted by a H2O/AcOH (0.1% v/v) (eluent A)
and ACN (eluent B). A linear gradient starting from 50% of B,
changing to 100% of B over 20 min, and returning to the initial
conditions over 10 min was used for all the compounds. For the
HPLC analysis, all target compounds (i.e., assessed in biological
assays) were ≥95% pure. Evaporation was carried out in vacuo using a
rotating evaporator. Silica gel flash chromatography was performed
using silica gel 60 Å (0.040−0.063 mm; Merck). Reactions was
monitored by TLC on Merck aluminum silica gel (60 F254) plates
that were visualized under a UV lamp (λ = 254 nm). Melting points
were determined on a Kofler hot-stage apparatus and are uncorrected.
3-Amino-2-hydroxy-4-methylpyridine (1). Pd/C (100.0 mg)
was added to a solution of the commercially available 2-hydroxy-4-
methyl-3-nitropyridine (1.00 g, 6.49 mmol) in methanol. The reaction
mixture was stirred under hydrogen at room temperature for 12 h and
then was filtered under vacuum using Celite. The filtrate was
evaporated under reduced pressure to afford the desired compound 1
as solid (0.80 g, 99%). 1H NMR (CDCl3 δ): 12.36 (bs,1H), 6.57 (d,
1H, J = 7.2 Hz), 5.88 (d, 1H, J = 7.2 Hz), 3.97 (bs, 2H), 2.25 (s, 3H).
N-(1,2-Dihydro-4-methyl-2-oxopyridin-3-yl)cycloheptane-
carboxamide (2). Cycloheptanecarboxylic acid (0.700 mL, 4.99
mmol) was dissolved in SOCl2 (2.60 mL, 36.5 mmol) in a vial under
nitrogen flux. The solution was stirred at 76 °C for 3 h and then the
excess of SOCl2 was removed by evaporation under nitrogen flux. The
obtained acyl chloride was added dropwise to a solution of the amino
derivative 1 (310 mg, 2.50 mmol) and triethylamine (0.700 mL, 4.99
mmol) in anhydrous toluene (46.5 mL) and anhydrous DMF (6.20
mL) in a round-bottom flask at 0 °C. The reaction mixture was stirred
at room temperature for 48 h. Then the solvent was removed under
reduced pressure to give a residue which was dissolved in CHCl3 and
washed three times with water. Subsequently, the organic phase was
dried over Na2SO4, filtered, and evaporated under reduced pressure.
The brown solid obtained was purified by flash chromatography on
silica gel (ethyl acetate, 2% acetic acid) to give a solid which was
triturated in hexane to afford 2 as white solid (372 mg, 60%). Mp: dec
>150 °C (crystallized from hexane). 1H NMR (CDCl3 δ): 7.62 (bs,
1H), 7.10 (d, 1H, J = 6.4 Hz), 6.26 (d, 1H, J = 6.8 Hz), 2.53−2.48
(m, 1H), 2.16 (s, 3H), 2.02−1.98 (m, 2H), 1.81−1.71 (m, 4H),
1.59−1.53 (m, 6H).
N-(5-Bromo-1,2-dihydro-4-methyl-2-oxopyridin-3-yl)-
cycloheptanecarboxamide (3). A solution of Br2 (0.11 mL, 2.08
mmol) in CHCl3 (2.1 mL) was added dropwise to a solution of the
compound 2 (518 mg, 2.08 mmol) in CHCl3 (3.5 mL) at room
temperature. Reaction mixture was stirred at room temperature
overnight and then was washed four times with a saturated aqueous
solution of Na2S2O3. The organic phase was dried over Na2SO4,
filtered, and evaporated under reduced pressure. The solid residue was
crystallized from hexane to give 3 as a white solid (578 mg, 85%). Mp:
217−219 °C. 1H NMR (CDCl3 δ): 7.40 (bs, 1H), 7.39 (s, 1H),
2.56−2.49 (m, 1H), 2.21 (s, 3H), 2.06−2.00 (m, 2H), 1.85−1.73 (m,
4H), 1.61−1.55 (m, 6H). 13C NMR (CDCl3 δ): 176.32, 158.04,
134.75, 128.17, 127.41, 100.81, 48.21, 31.57, 28.40, 26.47, 19.68.
HPLC analysis: retention time = 5.1 min; peak area, 95.5% (280 nm).
N-(5-Chloro-1,2-dihydro-4-methyl-2-oxopyridin-3-yl)-
cycloheptanecarboxamide (4). A solution of N-chlorosuccinimide
(270 mg, 2.02 mmol) in acetonitrile (2.0 mL) was added to a
suspension of the derivative 2 (500 mg, 2.02 mmol) in acetonitrile
(3.0 mL). The reaction mixture was refluxed overnight. Then, the
solvent was removed under reduced pressure and the residue was
treated with water and extracted with ethyl acetate. The organic phase
was dried over Na2SO4, filtered, and concentrated under reduced
pressure to give a yellow solid purified by flash chromatography on
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silica gel using ethyl acetate/petroleum ether 7:3 and 1% acetic acid as
eluent, to give a yellow solid which was triturated in hexane to afford
compound 4 as white solid (274 mg, 48%). Mp: 200 °C (dec),
(crystallized from hexane). 1H NMR (CDCl3 δ): 8.73 (bs, 1H), 7.52
(s, 1H), 7.29 (bs, 1H), 2.54 (m, 1H), 2.18 (s, 3H), 2.04−2.01 (m,
2H), 1.83−1.73 (m, 4H), 1.66−1.49 (m, 6H).
3-Amino-2-hydroxy-6-methylpyridine (5). Compound 5 was
prepared as described for compound 1, starting from 2-hydroxy-6-
methyl-3-nitropyridine. Yield: 99%. 1H NMR (CDCl3 δ): 12.20 (bs,
1H), 6.78 (d, 1H, J = 6.8 Hz), 6.09 (d, 1H, J = 6.8 Hz), 4.03 (bs, 2H),
2.10 (s, 3H).
N-(1,2-Dihydro-6-methyl-2-oxopyridin-3-yl)cycloheptane-
carboxamide (6). A solution of cycloheptanecarboxylic acid (0.870
mL, 6.32 mmol) in anhydrous DMF (15.70 mL) was stirred in an ice
bath. TBTU (2440 mg, 7.59 mmol) and triethylamine (2.40 mL,
17.70 mmol) were added at 0 °C. After 30 min, compound 5 (785
mg, 6.32 mmol) was added and the reaction mixture was stirred at 0
°C for 30 min and then at room temperature overnight. The solvent
was removed under reduced pressure. The solid residue was dissolved
in CHCl3 and washed with water. The organic phase was dried over
Na2SO4, filtered, and evaporated under reduced pressure. The brown
solid thus obtained was purified by flash chromatography on silica gel
using ethyl acetate/petroleum ether 8:2 as eluent to give a yellow
solid which was crystallized from hexane to afford compound 6 as
white solid (1.290 g). Yield: 82%. Mp: 182−185 °C. 1H NMR
(CDCl3 δ): 11.77 (bs, 1H), 8.39 (d, 1H, J = 7.6 Hz), 8.16 (bs, 1H),
6.09 (d, 1H, J = 7.6 Hz), 2.47−2.44 (m, 1H), 2.32 (s, 3H), 2.01−1.95
(m, 2H), 1.83−1.71 (m, 4H), 1.62−1.49 (m, 6H).
N-(5-Bromo-1,2-dihydro-6-methyl-2-oxopyridin-3-yl)-
cycloheptanecarboxamide (7). Compound 7 was prepared
starting from derivative 6, as described for compound 3, and it was
purified by flash chromatography on silica gel using ethyl acetate/
petroleum ether 7:3. Yield: 89%. 1H NMR (CDCl3 δ): 12.25 (bs,
1H), 8.64 (s, 1H), 8.10 (s, 1H), 2.50−2.41 (m, 1H), 2.01 (s, 3H),
1.75−1.61 (m, 6H), 1.84−1.76 (m, 4H), 1.99−1.94 (m, 2H).
N-(5-Chloro-1,2-dihydro-6-methyl-2-oxopyridin-3-yl)-
cycloheptanecarboxamide (8). Compound 8 was prepared
starting from derivative 6, as described for compound 4, and it was
purified by flash chromatography on silica gel using ethyl acetate/
petroleum ether 1:1. Yield: 19%. Mp: 240−246 °C (crystallized from
hexane). 1H NMR (CDCl3 δ): 11.99 (bs, 1H), 8.55 (s, 1H), 8.11 (bs,
1H), 2.50−2.48 (m, 1H), 2.39 (s, 3H), 2.01−1.96 (m, 2H), 1.85−
1.81 (m, 4H), 1.79−1.54 (m, 6H).
N-(1,2-Dihydro-5-fluoro-6-methyl-2-oxopyridin-3-yl)-
cycloheptanecarboxamide (9). 1-Chloromethyl-4-fluoro-1,4-
diazoniabicyclo[2.2.2]octanebis(tetrafluoroborate) (Selectfluor)
(1.200 g, 3.39 mmol) was added at room temperature to a suspension
of compound 6 (700 mg, 2.82 mmol) in acetonitrile. Reaction
mixture was refluxed for 12 h. Then, the solvent was removed under
reduced pressure and the residue was treated with ethyl acetate and
washed three times with water. The organic phase was dried over
Na2SO4, filtered, and evaporated under reduced pressure. The black
solid thus obtained was purified by flash chromatography on silica gel
using petroleum ether/ethyl acetate 1:1 as eluent to give compound 9
(52.0 mg, 0.196 mmol) as a black solid. Yield: 7%. Mp: 95−98 °C
(crystallized from hexane). 1H NMR (CDCl3 δ): 8.48 (d, 1H, J = 10.4
Hz), 8.16 (bs, 1H), 2.51−2.46 (m, 1H), 2.30 (d, 3H, J = 2.8 Hz),
2.01−1.95 (m, 2H), 1.81−1.75 (m, 4H), 1.62−1.53 (m, 6H).
3-Amino-2,4-dihydroxypyridine (10). Compound 10 was
prepared starting from 2,4-dihydroxy-3-nitropyridine, as described
for compound 1. Yield: 33%. 1H NMR (MeOD δ): 12.26 (bs,1H),
6.84 (d, 1H, J = 7.2 Hz); 6.13 (d, 1H, J = 7.2 Hz), 4.03 (bs, 2H).
N-(1,2-Dihydro-4-hydroxy-2-oxopyridin-3-yl)cycloheptane-
carboxamide (11). Compound 11 was prepared starting from
derivative 10, as described for compound 2, and it was purified by
trituration with MeOH and then with Et2O. Yield: 25%. Mp: dec
>130 °C (crystallized from hexane). 1H NMR (CDCl3 δ): 12.71 (bs,
1H), 11.28 (bs, 1H), 8.39 (s, 1H), 7.03 (d, 1H, J = 7.2 Hz), 6.08 (d,
1H, J = 7.2 Hz) 2.58−2.57 (m, 1H), 2.02−1.98 (m, 2H), 1.83−1.72
(m, 4H), 1.65−1.50 (m, 6H).
N-(5-Bromo-1,2-dihydro-4-hydroxy-2-oxopyridin-3-yl)-
cycloheptanecarboxamide (12). Compound 12 was prepared
starting from derivative 11, as described for compound 3, and it was
purified by flash chromatography on silica gel using ethyl acetate/
petroleum ether 7:3. Yield: 68%. 1H NMR (CDCl3 δ): 8.34 (bs, 1H),
7.35 (s, 1H), 2.60−2.55 (m, 1H), 2.02−1.98 (m, 2H), 1.83−1,71 (m,
4H), 1.61−1.51 (m, 6H).
N-[1,2-Dihydro-1-(4′-fluorobenzyl)-4-methyl-2-oxopyridin-
3-yl]cycloheptanecarboxamide (C1). An amount of 214.0 mg of
CsF (1.41 mmol) was added to a solution of of 1,2-dihydropyridin-3-
cycloheptanecarboxamide 2 (117.0 mg, 0.470 mmol) in anhydrous
DMF (1.40 mL). After 1 h at room temperature, 4-fluorobenzyl
chloride (0.17 mL, 1.41 mmol) was added dropwise and the mixture
was stirred at 50 °C overnight. After cooling, the reaction mixture was
concentrated under reduced pressure, treated with ice−water, and
then extracted with CH2Cl2. The organic phase was dried over
Na2SO4, filtered, and evaporated under reduced pressure. The yellow
oil obtained was purified by flash chromatography on silica gel using
petroleum ether/ethyl acetate (1:1) to give C1 as white solid (67.0
mg, 40%). Mp: 160−165 °C (crystallized from hexane). 1H NMR
(CDCl3 δ): 7.43 (bs, 1H), 7.28−7.25 (m, 2H), 7.04−7.00 (m, 3H),
6.10 (d, 1H, J = 7.2 Hz), 5.07 (s, 2H), 2.53−2.46 (m, 1H), 2.12 (s,
3H), 2.07−2.00 (m, 2H), 1.83−1.72 (m, 4H), 1.59−1.52 (m, 6H).
13C NMR (CDCl3 δ): 176.06, 162.65 (d, J = 246.0 Hz), 159.56,
142.40, 132.04 (d, J = 3.2 Hz), 131.67, 130.02 (d, J = 9.1 Hz), 125.85,
115.95 (d, J = 22.0 Hz), 110.21, 51.99, 48.04, 31.92, 28.27, 26.77,
19.83. HPLC analysis: retention time = 8.6 min; peak area 99.7%
(280 nm).
N-[5-Bromo-1,2-dihydro-1-(4′-fluorobenzyl)-4-methyl-2-ox-
opyridin-3yl]cycloheptanecarboxamide (C2). Compound C2
was prepared starting from derivative 3, as described for compound
C1, and it was purified by flash chromatography on silica gel using
petroleum ether/ethyl acetate 7:3 as eluent. Yield: 58% Mp: 167−170
°C (crystallized from hexane). 1H NMR (CDCl3 δ): 7.48 (bs, 1H),
7.33 (s, 1H), 7.30−7.28 (m, 2H), 7.06−7.02 (m, 2H), 5.05 (s, 2H),
2.53−2.47 (m, 1H), 2.15 (s, 3H), 2.06−1.99 (m, 2H), 1.81−1.71 (m,
4H), 1.59−1.52 (m, 6H). 13C NMR (CDCl3 δ): 176.08, 162.77 (d, J
= 246.0 Hz), 158.42, 142.07, 132.10, 131.34 (d, J = 4.1 Hz), 130.21
(d, J = 9.1 Hz), 126.60, 116.12 (d, J = 22.0 Hz), 104.08, 52.06, 47.94,
31.81, 28.22, 26.70, 20.67. HPLC analysis: retention time = 9.5 min;
peak area 95.5% (280 nm).
N-[1,2-Dihydro-1-(4′-fluorobenzyl)-5-(4′-methoxyphenyl)-
4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide (C3). A
mixture of Pd(OAc)2 (2.20 mg, 0.009 mmol) and PPh3 (11.80 mg,
0.045 mmol) in 2.50 mL of toluene was stirred under nitrogen at
room temperature. After 15 min, the suitable boronic acid (37.9 mg,
0.600 mmol), K2CO3 (62,2 mg, 0.450 mmol), and compound C2
(130.6 mg, 0.300 mmol) were added. Reaction mixture was stirred at
110 °C overnight. After cooling, the reaction was filtered under
vacuum using Celite, and the filtrate was evaporated under reduced
pressure. The residue was treated with water and extracted with
CHCl3. The combined organic layers were washed with brine, dried
over anhydrous sodium sulfate, and evaporated to give a residue
which was purified by flash chromatography on silica gel using
petroleum ether/ethyl acetate 8:2 as eluent affording C3 as oil (100
mg, 0.216 mmol). Yield: 72%. 1H NMR (CDCl3 δ): 7.57 (bs, 1H),
7.32−7.29 (m, 2H), 7.17−7.15 (m, 2H), 7.05−7.00 (m, 3H), 6.92−
6.90 (m, 2H), 5.12 (s, 2H), 3.83 (s, 3H), 2.56−2.51 (m, 1H), 2.07−
2.02 (m, 2H), 1.98 (s, 3H), 1.81−1.76 (m, 4H), 1.60−1.58 (m, 6H).
13C NMR (CDCl3 δ): 176.15, 162.18 (d, J = 245.0 Hz), 159.26,
158.70, 142.25, 135.89, 131.97 (d, J = 32 Hz), 130.92, 130.82, 130.07
(d, J = 8.6 Hz), 129.05, 125.85, 123.46, 115.92 (d, J = 22.0 Hz),
113.95, 55.42, 52.00, 47.89, 31.88, 28.26, 26.70, 18.50. HPLC
analysis: retention time = 13.2 min; peak area 98.2% (280 nm).
N-[1,2-Dihydro-1-(4′-fluorobenzyl)-4-methyl-2-oxo-5-phe-
nyl-pyridin-3-yl]cycloheptanecarboxamide (C4). Compound
C4 was prepared from compound C2, as described for compound
C3, and it was purified by crystallization from hexane. Yield: 45%.
Mp: 143−146 °C (crystallized from hexane). 1H NMR (CDCl3 δ):
7.54 (bs, 1H), 7.41−7.29 (m, 5H), 7.25−7.24 (m, 2H), 7.05−7.01
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(m, 3H), 5.12 (s, 2H), 2.56−2.51 (m, 1H), 2.07−2.02 (m, 2H), 1.99
(s, 3H), 1.83−1.77 (m, 4H), 1.60−1.53 (m, 6H). 13C NMR (CDCl3
δ): 176.05, 162.58 (d, J = 243.8 Hz), 158.72, 141.85, 136.78, 131.93
(d, J = 3.2 Hz), 131.00, 130.04 (d, J = 8.6 Hz), 129.67, 128.52,
127.72, 126.02, 123.77, 115.89 (d, J = 21.8 Hz), 51.98, 47.81, 31.85,
28.25, 26.67, 18.41. HPLC analysis: retention time = 13.5 min; peak
area 99.6% (280 nm).
N-[5-Chloro-1,2-dihydro-1-(4′-fluorobenzyl)-4-methyl-2-ox-
opyridin-3-yl]cycloheptanecarboxamide (C5). Compound C5
was prepared from compound 4, as described for compound C1, and
it was purified by flash chromatography on silica gel using petroleum
ether/ethyl acetate 7:3 as eluent to give a light yellow solid which was
triturated in hexane to afford C5 as white solid. Yield: 39%. Mp: 197−
199 °C (crystallized from hexane). 1H NMR (CDCl3 δ): 7.49 (bs,
1H), 7.30−7.27 (m, 2H), 7.21 (s, 1H), 7.06−7.02 (m, 2H), 5.06 (s,
2H), 2.53−2.48 (m, 1H), 2.14 (s, 3H), 2.06−2.00 (m, 2H), 1.81−
1.74 (m, 4H), 1.58−1.51 (m, 6H). 13C NMR (CDCl3 δ): 176.06,
162.72 (d, J = 246.0 Hz), 158.24, 141.17, 131.33 (d, J = 3.2 Hz),
130.17 (d, J = 8.6 Hz), 129.62, 126.64, 116.05 (d, J = 22.0 Hz),
115.75, 52.01, 47.83, 31.77, 28.19, 26.66, 17.86. HPLC analysis:
retention time = 11.6 min; peak area 96.8% (280 nM).
N-[1,2-Dihydro-1-(4′-fluorobenzyl)-6-methyl-2-oxopyridin-
3-yl]cycloheptanecarboxamide (D1). An amount of 35.2 mg
(0.879 mmol) of NaH (60% mineral oil dispersion) was added
portionwise to a solution of 1,2-dihydropyridin-3-cycloheptane-
carboxamide 6 (212 mg, 0.854 mmol) in DME (1.700 mL) and
anhydrous DMF (0.400 mL). After 10 min at 0 °C, LiBr (147.6 mg,
1.700 mmol) was added and the reaction mixture was stirred at room
temperature for 15 min. After that, 4-fluorobenzyl chloride (0.200
mL, 1.650 mmol) was added dropwise and the mixture was stirred at
65 °C overnight. After cooling, the solvent was removed under
reduced pressure and the obtained residue was dissolved in CHCl3
and washed with brine. The organic phase was dried over Na2SO4,
filtered, and evaporated under reduced pressure to obtain a residue
which was purified by flash chromatography on silica gel using
petroleum ether/ethyl acetate 8:2 as eluent giving D1 as oil (79.1 mg,
0.220 mmol). Yield: 26%. 1H NMR (CDCl3 δ): 8.31 (bs, 1H), 8.30
(d, 1H, J = 7.6 Hz), 7.11−7.08 (m, 2H), 6.99−6.96 (m, 2H), 6.09 (d,
1H, J = 7.6 Hz), 5.31 (s, 2H), 2.44−2.43 (m, 1H), 2.26 (s, 3H),
1.99−1.95 (m, 2H), 1.79−1.70 (m, 4H), 1.58−1.48 (m, 6H). 13C
NMR (CDCl3 δ): 176.44, 162.27 (d, J = 245.0 Hz), 158.75, 137.97,
131.86, 128.25 (d, J = 8.6 Hz), 127.36, 122.34, 115.93 (d, J = 22.1
Hz), 107.32, 48.58, 47.62, 31.69, 28.31, 26.64, 20.14. HPLC analysis:
retention time = 13.2 min; peak area 97.1% (280 nm).
N-[5-Bromo-1,2-dihydro-1-(4′-fluorobenzyl)-6-methyl-2-ox-
opyridin-3-y]cycloheptanecarboxamide (D2). Compound D2
was prepared from derivative 7, as described for compound D1, and it
was purified by flash column chromatography on silica gel using
petroleum ether/ethyl acetate 8:2 as eluent. Yield: 40%. Mp: 124−
127 °C (crystallized from hexane). 1H NMR (CDCl3 δ): 8.61 (s, 1H),
8.31 (bs, 1H), 7.12−7.09 (m, 2H), 7.04−7.00 (m, 2H), 5.39 (s, 2H),
2.48−2.43 (m, 1H), 2.42 (s, 3H), 2.02−1.94 (m, 2H), 1.82−1.71 (m,
4H), 1.63−1.54 (m, 6H). 13C NMR (CDCl3 δ): 176.33, 162.19 (d, J
= 246.0 Hz), 157.76, 135.64, 131.20 (d, J = 3.2 Hz), 128.05 (d, J = 8.1
Hz), 127.46, 125.78, 115.91 (d, J = 22.0 Hz), 101.53, 48.77, 48.23,
31.42, 28.18, 26.39, 19.49. HPLC analysis: retention time = 17.6 min;
peak area 98.1% (280 nM).
N-[1,2-Dihydro-1-(4′-fluorobenzyl)-5-phenyl-6-methyl-2-
oxopyridin-3-yl]cycloheptanecarboxamide (D3). Compound
D3 was prepared starting from derivative D2, as described for
compound C3, and it was purified by flash column chromatography
on silica gel using petroleum ether/ethyl acetate 8:2 as eluent. Yield:
13%. 1H NMR (CDCl3 δ): 8.45 (s, 1H), 8.38 (bs, 1H), 7.38−7.28
(m, 4H), 7.25−7.23 (m, 3H), 7.17−7.01 (m, 2H), 5.44 (s, 2H),
2.46−2.43 (m, 1H), 2.24 (s, 3H), 2.01−1.95 (m, 2H), 1.79−1.71 (m,
4H), 1.59−1.49 (m, 6H). 13C NMR (CDCl3 δ): 176.47, 162.29 (d, J
= 244.0 Hz), 158.22, 139.27, 135.05, 132.00, 129.84, 128.53, 128.25
(d, J = 8.6 Hz), 127.43, 126.75, 125.23, 121.35, 115.99 (d, J = 22.0
Hz), 48.46, 48.16, 31.68, 28.42, 26.60, 17.56. HPLC analysis:
retention time = 18.0 min; peak area 95.8% (280 nm).
N-[1,2-Dihydro-1-(4′-fluorobenzyl)-5-(4′-methoxyphenyl)-
6-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide (D4).
Compound D4 was prepared starting from compound D2, as
described for compound C3, and it was purified by flash column
chromatography on silica gel using petroleum ether/ethyl acetate 8:2
as eluent. Yield: 19%. 1H NMR (CDCl3 δ): 8.43 (s, 1H), 8.38 (bs,
1H), 7.17−7.13 (m, 4H), 7.05−7.01 (m, 2H), 6.90−6.88 (m, 2H),
5.43 (s, 2H), 3.83 (s, 3H), 2.48−2.43 (m, 1H), 2.23 (s, 3H), 2.00−
1.97 (m, 2H), 1.80−1.74 (m, 4H), 1.52−1.50 (m, 6H). 13C NMR
(CDCl3 δ): 176.43, 162.24 (d, J = 244.0 Hz), 158.93, 158.14, 135.03,
131.99 (d, J = 3.2 Hz), 130.89, 128.22 (d, J = 8.6 Hz), 126.61, 125.47,
120.95, 115.94 (d, J = 21.8 Hz), 113.90, 55.42, 48.44, 48.16, 31.65,
28.38, 26.58, 17.53. HPLC analysis: retention time = 17.3 min; peak
area, 99.0% (280 nm).
N-[5-Chloro-1,2-dihydro-1-(4′-fluorobenzyl)-6-methyl-2-ox-
opyridin-3-yl]cycloheptanecarboxamide (D5). Compound D5
was prepared starting from compound 8, as described for compound
D1, and it was purified by crystallization from hexane. Yield: 36%.
Mp: 116−119 °C (crystallized from hexane). 1H NMR (CDCl3 δ):
8.49 (s, 1H), 8.33 (bs, 1H), 7.12−7.09 (m, 2H), 7.04−7.00 (m, 2H),
5.37 (s, 2H), 2.46−2.43 (m, 1H), 2.38 (s, 3H), 2.04−1.94 (m, 2H),
1.81−1.71 (m, 4H), 1.61−1.48 (m, 6H). 13C NMR (CDCl3 δ):
176.39, 162.24 (d, J = 245.0 Hz), 157.56, 134.35, 131.26 (d, J = 3.2
Hz), 128.11 (d, J = 8.1 Hz), 127.37, 123.48, 115.95 (d, J = 22.0 Hz),
113.35, 48.50, 48.30, 31.47, 28.21, 26.44, 16.68. HPLC analysis:
retention time = 16.9 min; peak area 98.2% (280 nm).
N-[1,2-Dihydro-5-fluoro-1-(4′-fluorobenzyl)-6-methyl-2-ox-
opyridin-3-yl]cycloheptanecarboxamide (D6). Compound D6
was prepared starting from compound 9, as described for compound
D1, and it was purified by flash column chromatography on silica gel
using petroleum ether/ethyl acetate 8:2. Yield: 24%. 1H NMR
(CDCl3 δ): 8.43 (d, 1H, J = 10.4 Hz), 8.40 (bs, 1H), 7.14−7.11 (m,
2H), 7.04−7.00 (m, 2H), 5.32 (s, 2H), 2.48−2.43 (m, 1H), 2.25 (d,
3H, J = 3.2 Hz), 2.05−1.95 (m, 2H), 1.80−1.74 (m, 4H), 1.55−1.52
(m, 6H). 13C NMR (CDCl3 δ): 176.54, 162.33 (d, J = 245.0 Hz),
156.74, 145.52 (d, J = 224.2 Hz), 131.48 (d, J = 3.2 Hz), 128.30 (d, J
= 8.6 Hz), 127.23 (d, J = 13.0 Hz), 123.12 (d, J = 29.1 Hz), 116.02
(d, J = 21.0 Hz), 114.34 (d, J = 32.4 Hz), 48.45, 47.78, 31.56, 28.28,
26.56, 11.78. HPLC analysis: retention time = 15.1 min; peak area
96.3% (280 nm).
N-(5-Bromo-1,2-dihydro-1-(4-fluorobenzyl)-4-hydroxy-2-
oxopyridin-3-yl)cycloheptanecarboxamide (E1). Compound E1
was prepared from compound 12, as described for compound C1, and
it was purified by flash column chromatography on silica gel using
petroleum ether/ethyl acetate 8:2 as eluent. Yield: 8%. Mp: 73−76 °C
(crystallized from hexane). 1H NMR (CDCl3 δ): 13.46 (bs, 1H), 8.51
(bs, 1H), 7.30 (s, 1H), 7.28−7.24 (m, 2H), 7.08−7.03 (m, 2H), 5.06
(s, 2H), 2.61−2.52 (m, 1H), 2.05−1.97 (m, 2H), 1.85−1.68 (m, 4H),
1.62−1.44 (m, 6H). 13C NMR (CDCl3 δ): 178.70, 161.56, 132.50,
131.40, 129.94 (d, J = 8.6 Hz), 116.19 (d, J = 21.8 Hz), 112.40, 97.30,
51.88, 47.72, 31.85, 28.09, 26.50. HPLC analysis: retention time =
15.6 min; peak area 95.8% (280 nM).
Biological Evaluations. CHO Cells. CHO cells stably transfected
with cDNA encoding human cannabinoid CB1Rs or CB2Rs were
maintained at 37 °C and 5% CO2 in Gibco Ham’s F-12 nutrient mix
supplied by Fisher Scientific UK Ltd. that was supplemented with 2
mM L-glutamine, 10% FBS, and 0.6% penicillin−streptomycin, all also
supplied by Fisher Scientific UK Ltd., and with the disulfate salt of
G418 [(2R,3S,4R,5R,6S)-5-amino-6-{[(1R,2S,3S,4R,6S)-4,6-diamino-
3-{[(2R,3R,4R,5R)-3,5-dihydroxy- 5-methyl-4-(methylamino)oxan-2-
yl]oxy}-2-hydroxycyclohexyl]oxy}-2-[(1R)-1-hydroxyethyl]oxane-3,4-
diol; 600 mg·mL−1] supplied by Sigma-Aldrich UK. All cells were
exposed to 5% CO2 in their respective media and were passaged twice
a week using nonenzymatic cell dissociation solution. For membrane
preparation, cells were removed from flasks by scraping, centrifuging,
and then freezing as a pellet at −20 °C until required. Before use in a
radioligand binding assay, cells were defrosted, diluted in Tris buffer
(50 mM Tris-HCl and 50 mM Tris-base).
Radioligand Displacement Assay. The assays were carried out
with [3H]CP55940 and Tris binding buffer (50 mM Tris-HCl, 50
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mM Tri-base, 0.1% BSA, pH 7.4), total assay volume 500 μL. Binding
was initiated by the addition of transfected human CB1 or CB2 CHO
cell membranes (50 μg protein per well). All assays were performed at
37 °C for 60 min before termination by the addition of ice-cold Tris
binding buffer, followed by vacuum filtration using a 24-well sampling
manifold (Brandel cell harvester; Brandel Inc., Gaithersburg, MD,
USA) and Brandel GF/B filters that had been soaked in wash buffer at
4 °C for at least 24 h. Each reaction well was washed six times with a
1.2 mL aliquot of Tris-binding buffer. The filters were oven-dried for
60 min and then placed in 3 mL of scintillation fluid (Ultima Gold
XR, PerkinElmer, Seer Green, Buckinghamshire, U.K.). Radioactivity
was quantified by liquid scintillation spectrometry. Specific binding
was defined as the difference between the binding that occurred in the
presence and absence of 1 μM unlabeled CP55940. The
concentration of [3H]CP55940 used in our displacement assays was
0.7 nM. The compounds used in this investigation were stored as
stock solutions of 10 mM in DMSO, the vehicle concentration in all
assay wells being 0.1% DMSO. Each point on each graph represents
the mean of data obtained from six independent experiments. Each
experiment was performed in duplicate for each concentration.
[35S]GTPγS Assay. The assay was carried out in the presence of
[35S]GTPγS (0.1 nM), GDP (30 μM), GTPγS (30 μM), and CHO
cell membranes (1 mg/mL) overexpressing hCB1Rs or hCB2Rs. The
assay buffer contained 50 mM Tris, 10 mM MgCl2, 100 mM NaCl,
0.2 mM EDTA, and 1 mM DTT (dithiothreitol) at pH 7.4.
Incubations were carried out at 30 °C for 90 min in a total volume of
500 mL. The reaction was terminated by the addition of ice-cold wash
buffer (50 mM Tris and 1 mg/mL BSA, pH 7.4) followed by rapid
filtration under vacuum through Whatman GF/B glass-fiber filters
(presoaked in wash buffer), 24-well sampling manifold (Brandel Cell
Harvester; Brandel Inc., Gaithersburg, MD, USA), and Brandel GF/B
filters that had been soaked in wash buffer at 4 °C for at least 24 h.
Each reaction well was washed six times with a 1.2 mL aliquot of Tris-
binding buffer. The filters were oven-dried for 60 min and then placed
in 3 mL of scintillation fluid (Ultima Gold XR, PerkinElmer, Seer
Green, Buckinghamshire, U.K.). Bound radioactivity was determined
by liquid scintillation counting. Basal binding of [35S]GTPγS was
determined in the presence of 20 mM GDP and absence of
cannabinoid. Nonspecific binding was determined in the presence of
10 mM GTPγS. The compounds used in this investigation were
stored as stock solutions of 10 mM in DMSO, the vehicle
concentration in all assay wells being 0.1% DMSO. Each point on
CB1R graph represents the mean of data obtained from six
independent experiments. Each experiment was performed in
duplicate for each concentration. This protocol was also used to
obtain the data shown in the 2-AG and AEA CB2R graphs. Each point
on the CP55940 CB2R graph represents the mean of data obtained
from 12 independent experiments. Each experiment was performed in
duplicate for each concentration.
Dissociation Kinetic Assay. Dissociation kinetic assays were
performed with [3H]CP55940 and Tris binding buffer (50 mM Tris-
HCl, 50 mM Tris-base, 0.1% BSA, pH 7.4), total assay volume 500
μL. Dissociation was initiated by addition of transfected human CB1
or CB2 CHO cell membranes (50 μg protein per well). Dissociation
times of 0.5−120 min at 25 °C were used. To determine the
nonspecific binding, experiments were also performed in the presence
of a 1 μM concentration of the unlabeled ligand. All assays were
performed at 37 °C for 60 min before termination by the addition of
ice-cold Tris binding buffer, followed by vacuum filtration using a 24-
well sampling manifold (Brandel cell harvester; Brandel Inc.,
Gaithersburg, MD, USA) and Brandel GF/B filters that had been
soaked in wash buffer at 4 °C for at least 24 h. Each reaction well was
washed six times with a 1.2 mL aliquot of Tris-binding buffer. The
filters were oven-dried for 60 min and then placed in 3 mL of
scintillation fluid (Ultima Gold XR, PerkinElmer, Seer Green,
Buckinghamshire, U.K.). Radioactivity was quantified by liquid
scintillation spectrometry. Specific binding was defined as the
difference between the binding that occurred in the presence and
absence of 1 μM unlabeled CP55940. The concentration of
[3H]CP55940 used in our displacement assays was 0.7 nM. The
compounds used in this investigation were stored as stock solutions of
10 mM in DMSO, the vehicle concentration in all assay wells being
0.1% DMSO. Each point on the graph represents the mean of data
obtained from four independent experiments. Each experiment was
performed in duplicate for each concentration.
Data Analysis. Results were calculated as percentage changes
from a basal level (zero) of [3H]CP55940 binding (in the presence of
vehicle). GraphPad Prism 5.0 (GraphPad, San Diego, CA) was used
to construct sigmoidal log concentration−response curves and to
calculate values of EC50, Emax, SEM, and 95% confidence intervals. P
values of <0.05 were considered to be significant.
MAGL Inhibition Assay. Human recombinant MAGL and 4-
NPA substrate were from Cayman Chemical. The enzymatic reaction
was carried out at room temperature (final volume of 200 μL in 10
mM Tris buffer, pH 7.2, containing 1 mM EDTA and 0.1 mg/mL
BSA). A total of 150 μL of 4-NPA 133.3 μM (final concentration =
100 μM) was added to 10 μL of DMSO containing the appropriate
amount of compound, and the reaction was initiated by the addition
of 40 μL of MAGL (11 ng/well). After the reaction had proceeded for
30 min, absorbance values were then measured by using a Victor X3
microplate reader (PerkinElmer) at 405 nm.1 The assay was generated
in 96-well microtiter plates. Two reactions were also run: one reaction
containing no compounds and the second one containing neither
inhibitor nor enzyme.
Pharmacological in Vivo Study. Male CD-1 albino mice
(Envigo, Varese, Italy), weighing approximately 22−25 g at the
beginning of the experimental procedure, were used. Animals were
housed in CeSAL (Centro Stabulazione Animali da Laboratorio,
University of Florence) and used at least 1 week after their arrival.
Ten mice were housed per cage (size 26 cm × 41 cm); animals were
fed a standard laboratory diet and tap water ad libitum and kept at 23
± 1 °C with a 12 h light/dark cycle, light at 7 a.m. All animal
manipulations were carried out according to the Directive 2010/63/
EU of the European parliament and of the European Union council
(September 22, 2010) on the protection of animals used for scientific
purposes. The ethical policy of the University of Florence complies
with the Guide for the Care and Use of Laboratory Animals of the
U.S. National Institutes of Health (NIH Publication No. 85-23,
revised 1996; University of Florence assurance number A5278-01).
Formal approval to conduct the experiments described was obtained
from the Animal Subjects Review Board of the University of Florence.
Experiments involving animals have been reported according to
ARRIVE guidelines.32 All efforts were made to minimize animal
suffering and to reduce the number of animals used.
Oxaliplatin-Induced Neuropathic Pain Model. Mice treated
with oxaliplatin (2.4 mg kg−1) were administered ip on days 1−2, 5−
9, 12−14 (10 ip injections).27,33 Oxaliplatin was dissolved in 5%
glucose solution. Control animals received an equivalent volume of
vehicle. Behavioral tests were performed on day 15.
Cold Plate Test. The animals were placed in a stainless steel box
(12 cm × 20 cm × 10 cm) with a cold plate as floor. The temperature
of the cold plate was kept constant at 4 °C ± 1 °C. Pain-related
behavior (licking of the hind paw) was observed, and the time
(seconds) of the first sign was recorded. The cutoff time of the latency
of paw lifting or licking was set at 60 s.
Compounds Administration. C2 (1, 5, 10, 20 mg kg−1) was
dissolved in 1% carboxymethylcellulose and orally administered.
Measurements were performed 15, 30, 45, 60, and 75 min after
injection. Control mice were treated with vehicle. The MAGL
inhibitor F (1 mg kg−1 po; Cayman Chemical, USA) was dissolved in
1% carboxymethylcellulose and administered 15 min after C2 (1−10
mg kg−1 po). Measurements were performed 15, 30, 45, 60, and 75
min after C2 injection. The selective CB1R (SR141716A; Tocris
Bioscience, U.K.) and CB2R (SR144528; Tocris Bioscience, U.K.)
antagonists were dissolved in saline solution with 5% DMSO and 5%
Tween 20. Antagonists were administered ip 15 min before C2 (20
mg kg−1 po). The dosages of SR141716A and SR144528 were
according to previously published articles.34,35
Statistical Analysis. Behavioral measurements were performed
on 16 mice for each treatment carried out in 2 different experimental
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sets (8 animals for single experimental session). Results were
expressed as mean ± SEM. The analysis of variance of behavioral
data was performed by one way ANOVA, and a Bonferroni’s
significant difference procedure was used as post hoc comparison. P
values of less than 0.05 or 0.01 were considered significant.
Investigators were blind to all experimental procedures. Data were
analyzed using the “Origin 9” software (OriginLab, Northampton,
MA, USA).
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.jmed-
chem.8b00368.
Screening on CB1R of compounds C1−C5, D1−D6, E1,
and 3; effects of compounds C3 and D3 on [3H]-
CP55940 binding to CB1R; effects of compounds C1,
C3−C5, D1−D6, E1, and 3 on [3H]CP55940 binding
to CB2R; CB2R [
35S]GTPγS binding assays performed
in the presence of C2 only; compound C2-MAGL
inhibition analysis; 1H and 13C NMR spectra and HPLC
chromatograms of the final compounds (PDF)
Molecular formula strings for target compounds and
some data (CSV)
■ AUTHOR INFORMATION
Corresponding Author
*Phone: +39 050 2219548. Fax: +39 050 2210680. E-mail:
clementina.manera@unipi.it.
ORCID
Maria Digiacomo: 0000-0003-0653-6642
Tiziano Tuccinardi: 0000-0002-6205-4069
Clementina Manera: 0000-0002-7379-5743
Author Contributions
⊥P.G. and L.D.C.M. contributed equally to this work.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
This work was supported by grant from University of Pisa, Italy
(Progetti di Ricerca di Ateneo, PRA_2017_51) and supported
by FismFondazione Italiana Sclerosi Multipla-cod 2017/R/
16 and financed or cofinanced with the “5 per mille” public
funding.
■ ABBREVIATIONS USED
ECS, endocannabinoid system; CB1R, type 1 cannabinoid
receptor; CB2R, type 2 cannabinoid receptor; EC, endocanna-
binoid; AEA, anadamide; 2-AG, 2-arachidonoylglycerol;
MAGL, monoacylglycerol lipase; MeOH, methanol; SOCl2,
thionyl chloride; DMF, N,N-dimethylformamide; DMSO,
dimethyl sulfoxide; NEt3, triethylamine; CHCl3, chloroform;
CH2Cl2, dichloromethane; ACN, acetonitrile; TBTU, 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluorobo-
rate; DME, dimethoxyethane; TLC, thin layer chromatog-
raphy; 4-NPA, 4-nitrophenylacetate; EDTA, ethylenediamine-
tetraacetic acid; BSA, bovine serum albumin
■ REFERENCES
(1) Pacher, P.; Kunos, G. Modulating the endocannabinoid system
in human health and disease–successes and failures. FEBS J. 2013,
280, 1918−1943.
(2) Jourdan, T.; Szanda, G.; Rosenberg, A. Z.; Tam, J.; Earley, B. J.;
Godlewski, G.; Cinar, R.; Liu, Z.; Liu, J.; Ju, C.; Pacher, P.; Kunos, G.
Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic
nephropathy. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, E5420−8.
(3) Gatta-Cherifi, B.; Cota, D. New insights on the role of the
endocannabinoid system in the regulation of energy balance. Int. J.
Obes. 2016, 40, 210−219.
(4) Mazier, W.; Saucisse, N.; Gatta-Cherifi, B.; Cota, D. The
endocannabinoid system: pivotal orchestrator of obesity and
metabolic disease. Trends Endocrinol. Metab. 2015, 26, 524−537.
(5) Cassano, T.; Calcagnini, S.; Pace, L.; De Marco, F.; Romano, A.;
Gaetani, S. Cannabinoid receptor 2 signaling in neurodegenerative
disorders: from pathogenesis to a promising therapeutic target. Front.
Neurosci. 2017, 11, 30.
(6) Niu, J.; Huang, D.; Zhou, R.; Yue, M.; Xu, T.; Yang, J.; He, L.;
Tian, H.; Liu, X.; Zeng, J. Activation of dorsal horn cannabinoid CB2
receptor suppresses the expression of P2Y12 and P2Y13 receptors in
neuropathic pain rats. J. Neuroinflammation 2017, 14, 185.
(7) Fonseca, B. M.; Teixeira, N. A.; Correia-da-Silva, G.
Cannabinoids as modulators of cell death: clinical applications and
future directions. Rev. Physiol., Biochem. Pharmacol. 2017, 173, 63−88.
(8) Martínez-Pinilla, E.; Varani, K.; Reyes-Resina, I.; Angelats, E.;
Vincenzi, F.; Ferreiro-Vera, C.; Oyarzabal, J.; Canela, E. I.; Lanciego,
J. L.; Nadal, X.; Navarro, G.; Borea, P. A.; Franco, R. Binding and
signaling studies disclose a potential allosteric site for cannabidiol in
cannabinoid CB2 receptors. Front. Pharmacol. 2017, 8, 744.
(9) Price, M. R.; Baillie, G. L.; Thomas, A.; Stevenson, L. A.; Easson,
M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; Walker,
G.; Westwood, P.; Marrs, J.; Thomson, F.; Cowley, P.; Christopoulos,
A.; Pertwee, R. G.; Ross, R. A. Allosteric modulation of the
cannabinoid CB1 receptor. Mol. Pharmacol. 2005, 68, 1484−1495.
(10) Sabatucci, A.; Tortolani, D.; Dainese, E.; Maccarrone, M. In
silico mapping of allosteric ligand binding sites in type-1 cannabinoid
receptor. Biotechnol. Appl. Biochem. 2018, 65 (1), 21−28.
(11) Kulkarni, R.; Garai, S.; Janero, D. R.; Thakur, G. A. Design and
synthesis of cannabinoid 1 receptor (CB1R) allosteric modulators:
drug discovery applications. Methods Enzymol. 2017, 593, 281−315.
(12) Khurana, L.; Mackie, K.; Piomelli, D.; Kendall, D. A.
Modulation of CB1 cannabinoid receptor by allosteric ligands:
pharmacology and therapeutic opportunities. Neuropharmacology
2017, 124, 3−12.
(13) Morales, P.; Goya, P.; Jagerovic, N.; Hernandez-Folgado, L.
Allosteric modulators of the CB1 cannabinoid receptor: a structural
update review. Cannabis Cannabinoid Res. 2016, 1, 22−30.
(14) Feng, Z.; Alqarni, M. H.; Yang, P.; Tong, Q.; Chowdhury, A.;
Wang, L.; Xie, X. Q. Modeling, molecular dynamics simulation and
mutation validation for structure of cannabinoid receptor 2 based on
known crystal structures of GPCRs. J. Chem. Inf. Model. 2014, 54,
2483−2499.
(15) Shore, D. M.; Baillie, G. L.; Hurst, D. H.; Navas, F.; Seltzman,
H. H.; Marcu, J. P.; Abood, M. E.; Ross, R. A.; Reggio, P. H. Allosteric
modulation of a cannabinoid g protein- coupled receptor: binding site
elucidation and relationship to g protein signaling. J. Biol. Chem. 2014,
289, 5828−5845.
(16) Christopoulos, A.; Kenakin, T. G protein-coupled receptor
allosterism and complexing. Pharmacol. Rev. 2002, 54, 323−374.
(17) Bridges, T. M.; Lindsley, C. W. G-protein-coupled receptors:
from classical modes of modulation to allosteric mechanisms. ACS
Chem. Biol. 2008, 3, 530−541.
(18) Conn, P. J.; Christopoulos, A.; Lindsley, C. W. Allosteric
modulators of GPCRs: a novel approach for the treatment of CNS
disorders. Nat. Rev. Drug Discovery 2009, 8, 41−54.
(19) Slivicki, R. A.; Xu, Z.; Kulkarni, P. M.; Pertwee, R. G.; Mackie,
K.; Thakur, G. A.; Hohmann, A. G. Positive allosteric modulation of
cannabinoid receptor type 1 suppresses pathological pain without
producing tolerance or dependence. Biol. Psychiatry 2017,
DOI: 10.1016/j.biopsych.2017.06.032.
(20) Ignatowska-Jankowska, M.; Baillie, G. L.; Kinsey, S.; Crowe,
M.; Ghosh, S.; Owens, R. A.; Damaj, I. M.; Poklis, J.; Wiley, J. L.;
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b00368
J. Med. Chem. XXXX, XXX, XXX−XXX
K
Zanda, M.; Zanato, C.; Greig, I. R.; Lichtman, A. H.; Ross, R. A. A
Cannabinoid CB1 receptor-positive allosteric modulator reduces
neuropathic pain in the mouse with no psychoactive effects.
Neuropsychopharmacology 2015, 40, 2948−2959.
(21) Horswill, J. C.; Bali, U.; Shaaban, S.; Keily, J. F.; Jeevaratnam,
P.; Babbs, A. J.; Reynet, C.; Wong Kai In, P. PSNCBAM-1, a novel
allosteric antagonist at cannabinoid CB1 receptors with hypophagic
effects in rats. Br. J. Pharmacol. 2007, 152, 805−814.
(22) Navarro, H. A.; Howard, J. L.; Pollard, G. T.; Carroll, F. T.
Positive allosteric modulation of the human cannabinoid (CB1)
receptor by RTI-371, a selective inhibitor of the dopamine
transporter. Br. J. Pharmacol. 2009, 156, 1178−1184.
(23) Petrucci, V.; Chicca, A.; Glasmacher, S.; Paloczi, J.; Cao, Z.;
Pacher, P.; Gertsch, J. Pepcan-12 (RVD-hemopressin) is a CB2
receptor positive allosteric modulator constitutively secreted by
adrenals and in liver upon tissue damage. Sci. Rep. 2017, 7, 9560.
(24) Chicca, A.; Arena, C.; Bertini, S.; Gado, F.; Ciaglia, E.; Abate,
M.; Digiacomo, M.; Lapillo, M.; Poli, G.; Bifulco, M.; Macchia, M.;
Tuccinardi, T.; Gertsch, J.; Manera, C. Polypharmacological profile of
1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid
system. Eur. J. Med. Chem. 2018, 154, 155−171.
(25) Muccioli, G. G.; Labar, G.; Lambert, D. M. CAY10499, a novel
monoglyceride lipase inhibitor evidenced by an expeditious MGL
assay. ChemBioChem 2008, 9, 2704−2710.
(26) Guindon, J.; Hohmann, A. G. Cannabinoid CB2 receptors: a
therapeutic target for the treatment of inflammatory and neuropathic
pain. Br. J. Pharmacol. 2008, 153, 319−334.
(27) Di Cesare Mannelli, L.; Lucarini, E.; Micheli, L.; Mosca, I.;
Ambrosino, P.; Soldovieri, M. V.; Martelli, A.; Testai, L.; Taglialatela,
M.; Calderone, V.; Ghelardini, C. Effects of natural and synthetic
isothiocyanate-based H2S-releasers against chemotherapy-induced
neuropathic pain: role of Kv7 potassium channels. Neuropharmacology
2017, 121, 49−59.
(28) Brindisi, M.; Maramai, S.; Gemma, S.; Brogi, S.; Grillo, A.; Di
Cesare Mannelli, L.; Gabellieri, E.; Lamponi, S.; Saponara, S.; Gorelli,
B.; Tedesco, D.; Bonfiglio, T.; Landry, C.; Jung, K. M.; Armirotti, A.;
Luongo, L.; Ligresti, A.; Piscitelli, F.; Bertucci, C.; Dehouck, M. P.;
Campiani, G.; Maione, S.; Ghelardini, C.; Pittaluga, A.; Piomelli, D.;
Di Marzo, V.; Butini, S. Development and pharmacological character-
ization of selective blockers of 2-arachidonoyl glycerol degradation
with efficacy in rodent models of multiple sclerosis and pain. J. Med.
Chem. 2016, 59, 2612−2632.
(29) Chou, T. C. Drug combination studies and their synergy
quantification using the Chou-Talalay method. Cancer Res. 2010, 70,
440−446.
(30) Di Cesare Mannelli, L.; Pacini, A.; Bonaccini, L.; Zanardelli, M.;
Mello, T.; Ghelardini, C. Morphologic features and glial activation in
rat oxaliplatin-dependent neuropathic pain. J. Pain 2013, 14, 1585−
1600.
(31) Luongo, L.; Maione, S.; Di Marzo, V. Endocannabinoids and
neuropathic pain: focus on neuron−glia and endocannabinoid−
neurotrophin interactions. Eur. J. Neurosci. 2014, 39, 401−408.
(32) McGrath, J. C.; Lilley, E. Implementing guidelines on reporting
research using animals (ARRIVE etc.): new requirements for
publication in BJP. Br. J. Pharmacol. 2015, 172, 3189−3193.
(33) Cavaletti, G.; Tredici, G.; Petruccioli, M. G.; Donde, E.;
Tredici, P.; Marmiroli, P.; Minoia, C.; Ronchi, A.; Bayssas, M.;
Etienne, G. G. Effects of different schedules of oxaliplatin treatment
on the peripheral nervous system of the rat. Eur. J. Cancer 2001, 37,
2457−2463.
(34) Lake, K. D.; Compton, D. R.; Varga, K.; Martin, B. R.; Kunos,
G. Cannabinoid-induced hypotension and bradycardia in rats
mediated by CB1-like cannabinoidreceptors. J. Pharmacol. Exp.
Ther. 1997, 281, 1030−1037.
(35) Li, A. L.; Carey, L. M.; Mackie, K. M.; Hohmann, A. G.
Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and
Neuropathic Pain through a CB1 Mechanism that is Independent of
CB2 Receptors in Mice. J. Pharmacol. Exp. Ther. 2017, 362, 296−305.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b00368
J. Med. Chem. XXXX, XXX, XXX−XXX
L
